🧠AI AnalysisEvaluating Adjuvant Pembrolizumab for Triple-Negative Breast Cancer Post-Chemotherapy
Medical experts preview upcoming clinical trial data examining whether post-surgery immunotherapy can lower recurrence risks for high-risk breast cancer patients.